Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

NCT06836726 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Castration Resistant Prostate Cancer

Interventions

DRUG: Evofosfamide

Sponsor

University Health Network, Toronto

Collaborators

[object Object]